MMJ Recs

APRIL 1, 2024

From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

The Cannigma

MAY 9, 2023

However, in 2019, the Jordanian government announced its plans to conduct clinical trials on the use of cannabis for medical purposes. However, the government’s recent announcement of clinical trials on medical cannabis could be a sign of change in the future.

Law 52

Law Clinical Trials Chronic Pain Recreational 52

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to treat aging and longevity, autoimmune diseases, and COVID-19- associated depression and cytokine elevation.

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

Cannabis Law Report

AUGUST 26, 2019

Chronic pain. One area that reports looked closely was, use of medical marijuana to treat chronic pain. Chronic pain is a foremost cause of disability that affects more than 25 million adults in the U.S. Chronic pain is a foremost cause of disability that affects more than 25 million adults in the U.S.

Chronic Pain 45

Chronic Pain Clinical Trials Epilepsy Conditions 45

Leafwell

MARCH 11, 2019

How it works and what effect it has on the body is not precisely known, partially because far more clinical trials need to take place before we can say anything for sure, and partially because research on cannabinoids – even the non-psychoactive/non-intoxicating ones – is still restricted in many parts of the world.

Clinical Trials 68

Clinical Trials CBD Cannabinoids Chronic Pain 68

Cannabis Law Report

NOVEMBER 24, 2019

Chronic pain. Severe treatment-resistant epilepsy. Chronic pain. Do not offer the following to manage chronic pain in adults: nabilone. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

JUNE 7, 2022

On the contrary, researchers are leaning more towards CBD as a beneficial chemical with therapeutic effects on various physical and mental health problems, from anxiety to chronic pain. Relieves Chronic Pain. Other studies found encouraging results on neuropathic pain, arthritis pain, and multiple sclerosis.

Chronic Pain 52

Chronic Pain CBD Digestion Edibles 52

Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd.

Epilepsy 40

Epilepsy Research and Development Clinical Trials Chronic Pain 40

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death.

Research and Development 118

Research and Development Education Agriculture Patients 118

Canna Care Docs

DECEMBER 16, 2020

Chronic pain. One of the most widespread uses of medical marijuana is for chronic pain. Next to chronic pain, treatment for multiple sclerosis is the second most common reason people seek medical marijuana in the US. Multiple sclerosis.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. For example, most statin drugs can cause memory issues, muscle pain, fatigue and muscle weakness. Epilepsy & behavior case reports 9 (2018): 10. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

Leafwell

MARCH 11, 2020

How it works and what effect it has on the body is not precisely known, partially because far more clinical trials need to take place before we can say anything for sure. Cannabidiol (CBD) is still a big mystery in many ways. Research even into non-psychoactive/non-intoxicating cannabinoids is restricted in many parts of the world.

Clinical Trials 10

Clinical Trials CBD Cannabinoids Chronic Pain 10

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Cannabis Law Report

NOVEMBER 25, 2021

Epilepsy Treatment. This study is, of course, well-vetted, and has offered plenty of hope to sufferers of epilepsy. According to various clinical trials, individuals who took CBD before speaking publicly in front of a big audience were able to remain calm and deliver their remarks with relative ease. Chronic Pain.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., This is because Epidiolex has been proven an effective treatment after going through various clinical trials. after its consumption.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

MMJ Recs

JULY 5, 2024

Medical Uses of THC Let’s explore the diverse medical uses of THC, highlighting its efficacy in alleviating chronic pain, its comparison with traditional painkillers, its role in combating nausea and stimulating appetite, its potential benefits for neurological disorders, and its complex interaction with mental health conditions.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain CBD 40

Cannabis Law Report

NOVEMBER 18, 2021

“Oravax has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial for its oral COVID-19 vaccine, and preparations to begin the trial are underway. Oravax is also preparing to commence clinical trials in Israel.”.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals.

Research and Development 40

Research and Development Clinical Trials Pharmaceutical Chronic Pain 40

Miss Marijuana

MARCH 15, 2021

Many people tout this strain’s powerful effect on their lives, and it will be curious to see what the medical community does once clinical trials are initiated. Chronic stress. Chronic Pain. Ringo’s Gift may help with the following conditions: Anxiety. Depression. Muscle Spasms. Inflammation.

Strains 52

Strains Indica Sativa Hybrid 52

Cannabis Law Report

NOVEMBER 10, 2021

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 Forward-Looking Statement.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Dr. Chapman Bio. Chapman has operated Chapman Pharmaceutical Consulting, Inc.,

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

JULY 12, 2019

The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

MMJ Recs

DECEMBER 22, 2023

Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. One significant factor is the recognition of the opioid crisis and the need for alternative pain management strategies.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Alchimia

FEBRUARY 1, 2022

Recent scientific studies have proven that cannabidiol contains the following therapeutic properties: Anticonvulsant : especially suitable to treat Dravet syndrome, a very aggressive type of childhood epilepsy. More research and clinical trials on the matter, especially its long-term effects, are still needed. Drowsiness.

CBD 52

CBD Epilepsy Research and Development Cannabinoids 52

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Chronic Pain 40

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. for its MET for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

JANUARY 5, 2022

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Treatment 40

Cannabis Law Report

OCTOBER 1, 2021

Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. About Noble Capital Markets, Inc.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials Chronic Pain 40

Green Relief

MAY 13, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. It is the most commonly identified cause of epilepsy among adults. CBD produces no intoxicating effects, no THC -like high, and its use does not lead to tolerance.

THC 64

THC CBD Cannabinoids Research and Development 64

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. There’s the one drug, one target, cannabis is multiple active ingredients and acts on multiple targets in the body.

Legalization 130

Legalization Patients Education Dispensary 130